Abstract: Methods of prevention of symptomatic malaria in a malaria-naïve, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naïve subjects.

Abstract: The present invention relates to nutritional compositions intended to prevent or treat regurgitations in infants and young children without altering, or even improving, their gut motility and/or for preventing and/or treating intestinal disorders of the infant or child. The invention also concerns the process for manufacturing this composition.

Abstract: The present invention relates to nutritional compositions intended to prevent or treat regurgitations in infants and young children without altering, or even improving, their gut motility and/or for preventing and/or treating intestinal disorders of the infant or child. The invention also concerns the process for manufacturing this composition.

Abstract: The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described.

Abstract: The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described.

Abstract: The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described.

Abstract: A continuous process for forming a transdermal patch which comprises the steps of: continuously feeding a strip of material comprising a layer of permeable membrane; continuously feeding into close proximity and in face-to-face relationship with the first strip a second strip formed of impermeable backing material; passing the first and second strips together through a filling and sealing station in which the material containing an active substance is introduced between the strips and pouches are formed by first sealing devices which seal the strips together in a longitudinal direction of the strips and second sealing devices which seal the strips together in a transverse direction of the strips; the size of the pouches being adjusted by adjusting the number position and/or frequency of operation of the first sealing devices and/or by adjusting the number position and/or frequency of operation of the second sealing devices.

Abstract: Treating a patient for neuro-muscular incontinence by administering a thiol-S-(2-diethyl-aminoethyl)-ester compound selected from the group consisting of trimethylacetyl-thio-S-(2-diethylaminoethyl)-ester, 1-cyclohexyl-1-phenylacetyl-thiol-S-(2-diethylaminoethyl)-ester, palmitoyl-thio-S-(2-diethylaminoethyl)-ester, 4-t-butyl-benzoyl-thiol-S-(2-diethylaminoethyl)-ester, phenylacetyl-thio-S-(2-diethylaminoethyl)-ester, 4-phenyl-butyryl-thio-S-(2-diethylaminoethyl)-ester, and 2-ethyl-butyryl-thio-S-(2-diethylaminoethyl)-ester.

Abstract: A new class of anti-spasmodic compounds having two branch chains is provided. The compounds have the general formula: ##STR1## where Y is H or OH;j is an integer from 0 to 4;k is an integer from 0 to 4, and whereinm is an integer from 1 to 4;n is an integer from 1 to 4;p is an integer from 1 to 4; andX may be nonexistent or may be O, S, NH or CH.sub.2 or salts thereof, but when X is nonexistent the terminal group in which both the n-chain and the p-chain is a methyl group. ##STR2## The reaction was performed under reflux condensation. Following the reaction, which was usually complete within a few hours, the acid chlorides were vacuum distilled and reacted with a thiol compound as described above.The compounds of this invention are anti-muscarinic agents (cholinergic-muscarinic receptor antagonists) which inhibit the actions of acetylcholine on autonomic effectors innervated by postganglionic cholinergic nerves as well as on smooth muscle that lacks cholinergic innervation.

Abstract: A new class of anti-spasmodic compounds having two branch chains is provided. The compounds have the general formula ##STR1## where R.sub.2 is a radical selected from the group consisting of ##STR2## where m is an integer from 0 to 3.

Abstract: A new method of treating a patient suffering from smooth muscle spasms involves treatment with a class of anti-spasmodic thioester compounds having a heterocyclic ring containing the nitrogen atom of a secondary or tertiary amine or a bicycloheterocyclic ring system containing the nitrogen atom of a secondary or tertiary amine. These compounds have the general formula I ##STR1## wherein: n is an integer from 0 to 2;R.sub.1 is aryl or cycloalkyl;R.sup.2 is hydrogen or hydroxyl; andR.sub.

Abstract: p is an integer from one to three;NR is selected from the group consisting of pyrrolidino, piperidino, morpholino and dialkylamino containing a total of two to eight carbon atoms either straight chain or branched; or pharmaceutically acceptable salts thereof.

Abstract: A new method of treating a patient suffering smooth muscle spasm comprises administering to the patient an effective amount of anti-spasmodic compound having the general formula: ##STR1## where R is selected from the group consisting of: ##STR2## wherein W is CH.sub.2, NH, O or S, ##STR3## wherein Y is an alicyclic ring ring having 3-12 carbon atoms, and ##STR4## the total number of carbon atoms in R is equal to or less than 20. Furthermore, m is an integer from 1 to 4, n is an integer from 1 to 4, p is an integer from 1 to 4 and q is an integer from 1 to 4. X may be nonexistent or may be 0, S, NH or CH.sub.2 or salts thereof. However, when X is nonexistent the terminal group in both the n-chain and the p-chain is a methyl group provided that a is zero or 1 and when a is 1, X is selected from the group consisting of 0, S, and CH.sub.

Abstract: A new class of anti-spasmodic compounds having two branch chains and containing quaternary nitrogen is provided. The compounds have the general formula: ##STR1## wherein R.sub.1 and R.sub.2 are defined hereinbelow and m is an integer from 0 to 3.

Abstract: A new class of anti-spasmodic thioester compounds having a heterocyclic ring containing the nitrogen atom of a secondary or tertiary amine or a bicycloheterocyclic ring system containing the nitrogen atom of a secondary or tertiary amine. These compounds have the general formula I ##STR1## wherein: n is an integer from 0 to 2;R.sub.1 is aryl or cycloalkyl;R.sub.2 is hydrogen or hydroxyl; andR.sub.

Abstract: A method for inhibiting unplanned or premature detrusor muscle contractions while at the same time increasing the force of contraction of the detrusor muscle is provided. The method comprises administering to the patient a di-N-substituted aminoethyl ester of diphenylthioacetic acid having the formula: ##STR1## in which R represents a disubstituted amino radical of the group consisting of the diethylamino group, the morpholino group or the piperidino group.

Abstract: A new class of anti-spasmodic compounds having two branch chains is provided. The compounds have the general formula: ##STR1## where R, X, m, n and p are defined hereinbelow.

Abstract: A new class of anti-spasmodic compounds having two branch chains is provided. The compounds have the general formula: ##STR1## wherein the substituents are defined hereinbelow.

Abstract: A new class of anti-spasmodic compounds having three branch chains is provided. These compounds have the general formula: ##STR1## where R.sub.1, R.sub.2 and R.sub.3 are saturated straight chain or branched alkyl groups contained from 1 to 8 carbon atoms, and are separated or linked to one another to form an aliphatic ring system. k is an integer from 0 to 5, and the total number of carbon atoms in R.sub.1 plus R.sub.2 plus R.sub.3 plus k are equal to or less than 12. Furthermore, l is an integer from 1 to 3, m is an integer from 1 to 3, n is an integer from 1 to 3, and X may be nonexistent or may be O, S, NH or CH.sub.2 or salts thereof. However, when X is nonexistent the terminal group in both the m chain and the n chain is a methyl group.

Abstract: A new class of anti-spasmodic thioester compounds having a heterocyclic ring containing the nitrogen atom of a secondary or tertiary amine or a bicycloheterocyclic ring system containing the nitrogen atom of a secondary or tertiary amine. These compounds have the general formula I ##STR1## wherein: =n is an integer from 0 to 2;R.sub.1 is aryl or cycloalkyl;=R.sub.2 is hydrogen or hydroxyl; andR.sub.